Aptose Gets FDA Fast-Track Designation for HM43239
04 May 2022 - 10:22PM
Dow Jones News
By Colin Kellaher
Aptose Biosciences Inc. on Wednesday said the U.S. Food and Drug
Administration granted fast-track designation to HM43239 for the
treatment of patients with relapsed or refractory acute myeloid
leukemia with FLT3 mutation.
The Toronto clinical-stage oncology company is currently
conducting a Phase 1/2 study of HM43239 in patients with the cancer
of the blood and bone marrow.
The FDA's fast-track program is designed to facilitate the
development and expedite the review of treatments for serious or
potentially life-threatening illnesses with high unmet medical
needs. The agency previously granted orphan-drug designation to
HM43239 for treatment of acute myeloid leukemia in 2018.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 04, 2022 08:07 ET (12:07 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Aptose Biosciences (TSX:APS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptose Biosciences (TSX:APS)
Historical Stock Chart
From Apr 2023 to Apr 2024
Real-Time news about Aptose Biosciences Inc (Toronto Stock Exchange): 0 recent articles
More Aptose Biosciences Inc News Articles